Colgate-Palmolive (CL)
Makes Colgate oral care, Palmolive household products and Hill's specialty pet nutrition.
Something off on this page? Send us feedback.
Sells toothpaste, toothbrushes, soap, deodorant, household cleaners, skin care and Hill's specialty pet food through retailers, distributors, veterinarians and e-commerce channels worldwide. Most revenue comes from outside the United States, and consumer products are managed by geography while pet nutrition is reported separately.
Builds a global consumer-products portfolio around Oral, Personal and Home Care and Hill's Pet Nutrition. Colgate toothpastes, toothbrushes and mouthwashes anchor oral care; Palmolive, Softsoap and Irish Spring span soaps and body care, while Ajax and Fabuloso cover household cleaning. EltaMD, Filorga and PCA SKIN add skin health.
Hill's sells everyday and therapeutic dog-and-cat nutrition under Science Diet and Prescription Diet through pet retailers, veterinarians and e-commerce channels. Prime100 adds fresh pet food in Australia. Science-led product development, advertising and broad retail distribution support category penetration across developed and emerging markets.
Most sales come from outside the United States. Consumer products are managed through four geographic divisions, while Hill's is reported separately; exposure includes foreign-currency swings, retailer bargaining power, commodity costs and global product regulations.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Piper Sandler | Reiterate | Rating: —Target: $92 | Target: $95 |
| Sep 11, 2026 | UBS | Downgrade | ||
| Sep 11, 2026 | RBC Capital | Initiate | Rating: — | |
| Sep 11, 2026 | Bernstein | Upgrade | ||
| Sep 11, 2026 | Citigroup | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.37B · Total debt $7.86B · Total assets $16.79B · Shareholders' equity $236.0M
- Revenue
- $5.36B
- Operating income
- $1.02B
- Net income
- $693.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | 84.78% | 675.81M shares | |
|---|---|---|---|
| 2,076 holders · as of Jun 30, 2026 | |||
| Insiders | 0.13% | 1.00M shares | |
| 20 holders · as of Sep 18, 2026 | |||
| Other | 15.09% | 120.36M shares | |
| remainder | |||
797.17M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.77% | 69.92M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.55% | 52.25M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.90% | 47.02M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 3.50% | 27.91M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 3.01% | 24.02M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Panagiotis Tsourapas | officer: COO, CD, EMEA, APac, Skin | −10,000 | $92.05 |
| Aug 6, 2026 | John T. Cahill | director | −4,170 | $93.37 |
| Aug 5, 2026 | Noel R. Wallace | director, officer: Chairman, President & CEO | −161,021 | $92.52 |
| Aug 4, 2026 | Noel R. Wallace | director, officer: Chairman, President & CEO | −161,021 | $91.92 |
| May 15, 2026 | Gregory Malcolm | officer: EVP and Controller | −2,300 | $88.44 |
- Procter & Gamble
Head-to-head rival across oral care, personal care, and home care worldwide.
- Unilever (ADR)
Oral, personal, and home care rival with dominant emerging-market share.
- Haleon (ADR)
Dominant in therapeutic oral care — sensitivity, gum health, and denture care.
- Church & Dwight
Oral care and personal care challenger via Arm & Hammer and TheraBreath.
- Kenvue
Mouthwash rival via Listerine; skin health overlap via Neutrogena and Aveeno.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Colgate-Palmolive | $87.21 | +1.10% | $69.02B | 34.2 | 22.2 | 3.3 | +4.9% |
| Procter & Gamble | $147.80 | +1.17% | $347.33B | 22.1 | 21.1 | 4.0 | +1.5% |
| Unilever (ADR) | $62.78 | +0.99% | $133.93B | 21.1 | — | 2.5 | −17.9% |
| Haleon (ADR) | $9.29 | −0.80% | $41.22B | 19.5 | — | 2.8 | +3.7% |
| Church & Dwight | $96.31 | +0.86% | $22.62B | 30.8 | 24.7 | 3.6 | +1.6% |
| Kenvue | $17.90 | +1.27% | $33.93B | 20.3 | 15.0 | 2.2 | +3.0% |
| Median | 21.1 | 21.1 | 2.8 | +1.6% |